Recurrent/refractory of ovarian cancer ascits
Conditions
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
Male
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. In patients with ascites confirmed by B-ultrasound, the degree of ascites is 2 and 3; (EASL guideline and ICA consensus); 2. Patients diagnosed as ovarian cancer by pathology or clinical diagnosis, and patients with ascites exfoliative cytology found tumor cells; 3. Patients who have received at least one protocol standard anti-tumor treatment; 4. Patients who have not received local intraperitoneal administration in the past 4 weeks; 5. Patients with stable vital signs, Karnofsky = 70 and expected survival time greater than 3 months; 6. patients aged 18-75 years; 7. For patients with normal hematopoiesis, the blood routine test: Hgb >=90g/L, WBC >=2.5x10^9/L (neu >=1.5x10^9/L), PLT >=90x10^9/L; 8. The coagulation function was normal without bleeding tendency (INR =60ml / min; 11. The patient must obtain a written informed consent before giving any operation related to the clinical study, which shall be signed and dated by himself.
Exclusion criteria
Exclusion criteria: 1. Patients with non malignant ascites; 2. Patients with other serious cardiopulmonary diseases; 3. Patients with extensive abdominal adhesions; encapsulated peritoneal effusion; intestinal obstruction; history of intestinal perforation; patients with cachexia with terminal extensive metastasis; 4. Women who are breastfeeding, pregnant or preparing for pregnancy; 5. Patients with severe hypoproteinemia whose ALB is less than 30g / L; 6. Patients who are known to be allergic to test sample ingredients or their analogues; 7. Patients with other severe, acute or chronic diseases that may interfere with the interpretation of the results of the study, who are not suitable for the clinical trial according to the judgment of the investigator; 8. Patients with cognitive impairment or poor treatment compliance as determined by researchers; 9. Patients who participated in other clinical trials within 4 weeks; 10. patients who are not considered suitable for clinical trials by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR of malignant ascites; | — |
Secondary
| Measure | Time frame |
|---|---|
| QOL;Tumor markers in ascites; | — |
Countries
China
Contacts
Public ContactXingsheng Yang
Qilu Hospital of Shandong University
Outcome results
None listed